Hema M, Nagendrakumar SB, Yamini R, et al. Chimeric tymovirus-like particles displaying foot-and-mouth disease virus non-structural protein epitopes and its use for detection of FMDV-NSP antibodies. Vaccine. 2007;25:4784-4794.
Domingo E, Escarmis C, Baranowski E, et al. Evolution of foot-and-mouth disease virus. Virus Res. 2003;91:47-63.
Golde WT, Pacheco JM, Duque H, et al. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine. 2005;23:5775-5782.
Paton DJ, Valarcher JF, Bergmann I, et al. Selection of foot and mouth disease vaccine strains – a review. Rev Sci Tech. 2005;24:981-994.
Lefebvre DJ, De Vleeschauwer AR, Goris N, et al. A thiazepino [4,5-a] benzimidazole derivative hampers the RNA replication of Eurasian serotypes of foot-and-mouth disease virus. Biochem Bioph Res Co. 2014;455:378-381.
Biedenkopf N, Lange-Grunweller K, Schulte FW, et al. The natural compound silvestrol is a potent inhibitor of Ebola virus replication. Antivir Res. 2017;137:76-81.
Cencic R, Pelletier J. Hippuristanol—a potent steroid inhibitor of eukaryotic initiation factor 4A. Translation. 2016;4(1):e1137381.
Sadlish H, Galicia-Vazquez G, Paris CG, et al. Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem Biol. 2013;8(7):1519-1527.
Tillotson J, Kedzior M, Guimaraes L, et al. ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A. Bioorg Med Chem Lett. 2017;27:4082-4085.
Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977;72:323-330.
Jin J, Jiang DZ, Mai WY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia. 2006;20:1361-1367.
Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia. 2009;23:1446-1454.
Romero MR, Serrano MA, Efferth T, Alvarez M, Marin JJ. Effect of cantharidin, cephalotaxine and homoharringtonine on "in vitro" models of hepatitis B virus (HBV) and bovine viral diarrhoea virus (BVDV) replication. Planta Med. 2007;73:552-558.
Kaur P, Thiruchelvan M, Lee RC, et al. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother. 2013;57:155-167.
Cao J, Forrest JC, Zhang X. A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res. 2015;114:1-10.
Dong HJ, Wang ZH, Meng W, et al. The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo. Viruses. 2018;10:10.
Kim JE, Song YJ. Anti-varicella-zoster virus activity of cephalotaxine esters in vitro. J Microbiol. 2019;57:74-79.
Li SF, Shao JJ, Zhao FR, et al. Antiviral activity of porcine interferon delta 8 against foot-and-mouth disease virus in vitro. Int Immunopharmacol. 2018;59:47-52.
Zhao FR, Xie YL, Liu ZZ, et al. Lithium chloride inhibits early stages of foot-and-mouth disease virus (FMDV) replication in vitro. J Med Virol. 2017;89:2041-2046.
